Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report

Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed follow...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of translational medicine Jg. 7; H. 5; S. 106
Hauptverfasser: Bender, Laura, Meyer, Guillaume, Quoix, Elisabeth, Mennecier, Bertrand
Format: Journal Article
Sprache:Englisch
Veröffentlicht: China 01.03.2019
Schlagworte:
Anaplastic lymphoma kinase rearrangement (ALK rearrangement)
diffuse interstitial pneumonitis
ceritinib
non-small cell lung cancer (NSCLC)
ISSN:2305-5839, 2305-5839
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.
Bibliographie:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2305-5839
2305-5839
DOI:10.21037/atm.2019.01.24